retatrutide triple agonist gip glp-1 glucagon phase 3 2025 π¨ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. π Mean body weight change at 80 weeks: β¬οΈ ADA 2026: Retatrutide Revolution
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 29 - Sep 3










:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)




:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)













